Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Influenza Vaccination or Infection in Children
NCT03673345Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Fluzone Trivalent in influenza (8 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Frequency of CD4 T Cells With a Given Functional Potential at Year 2. Started Sep 2018; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03673345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673345.